Investment Summary |
|
|---|---|
| Date | 2021-11-16 |
| Target | Ignis Therapeutics |
| Sector | Life Science |
| Investor(s) | HBM Partners |
| Deal Type | Venture |
SEARCH BY
| Category | Private Equity Firm |
|---|---|
| Founded | 2001 |
| PE ASSETS | 2.1B USD |
| Size | Large |
| Type | Sector Focused |
HBM Partners is a private investment firm focused on investing in entrepreneurial biopharma and other healthcare-related companies in Europe, North America, India and other Emerging Markets. HBM looks to invest $5 to $50 million per transaction and will consider private and public companies. HBM Partners was established in 2001 and is headquartered in Zug, Switzerland.
| DEAL STATS | # |
|---|---|
| Overall | 59 of 65 |
| Sector: Life Science M&A | 52 of 56 |
| Type: Venture M&A Deals | 47 of 52 |
| Country: China M&A | 7 of 7 |
| Year: 2021 M&A | 12 of 15 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2021-11-11 |
Acrivon
Watertown, Massachusetts, United States Acrivon is a proprietary, streamlined approach to develop patient selection tumor biopsy tests, called OncoSignature tests. Company’s lead molecule ACR-368 is a potent, selective inhibitor of CHK1 and CHK2 which has shown deep durable single agent activity, including complete responses, in a proportion of patients across several Phase 2 studies of platinum-resistant ovarian cancer and in squamous cell cancers, including anal cancer for which FDA has granted orphan drug designation. Acrivon was founded in 2018 and is based in Watertown, Massachusetts. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2021-12-07 |
Freenome
South San Francisco, California, United States Freenome develops blood-based tests for early cancer detection, applying its proprietary multiomics platform, deep expertise in molecular biology and advanced machine learning. Freenome was founded in 2014 and is based in South San Francisco, California. |
Buy | - |
